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HIV-1post-integration latency inCD4+ lymphocytes is
responsible for viral persistence despite treatment,
but mechanisms involved in the establishment of
latent viral reservoirs are not fully understood. We
determined that both interleukin 2 (IL-2) and IL-7
induced SAMHD1 phosphorylation in T592, abro-
gating its antiviral activity. However, IL-7 caused a
much more profound stimulatory effect on HIV-1
reverse transcription and integration than IL-2 that
required chemokine co-stimulation. Both cytokines
barely induced transcription due to low NF-kB
induction, favoring the establishment of latent re-
servoirs. Effect of IL-7 on SAMHD1 phosphoryla-
tion was confirmed in IL-7-treated patients (ACTG
5214 study). Dasatinib—a tyrosine-kinase inhibitor—
blocked SAMHD1 phosphorylation induced by IL-2
and IL-7 and restored HIV-1 restriction. We propose
that gc-cytokines play a major role in the reservoir
establishment not only by driving homeostatic prolif-
eration but also by increasing susceptibility of CD4+
lymphocytes to HIV-1 infection through SAMHD1
inactivation.
INTRODUCTION
Persistent HIV-1 infection is due to its capacity to integrate into
the host cell DNA where the provirus may persist in a latent
form. Antiretroviral treatment (ART) controls viral replication but
cannot eliminate this latent reservoir (Finzi et al., 1999; Siliciano
et al., 2003). A very small number of these residual, latently in-
fected cells may be sufficient to refuel viral replication and
replenish the reservoir if ART fails or is interrupted (Henrich
et al., 2014). Resting memory CD4+ T cells, preferentially stem
cell memory (Buzon et al., 2014) and central memory (Chomont
et al., 2009), constitute the main reservoir for HIV-1. This reser-
voir is established very early after infection (Whitney et al.,
2014), but its size is quite low in patients on ART. It has been2100 Cell Reports 14, 2100–2107, March 8, 2016 ª2016 The Authorsrecently estimated between 10 and 100 replication-competent
latent provirus per million resting CD4+ T cells (Ho et al., 2013).
In latent state, HIV-1 persists unscathed by immune response
or ART, but T cell activation resumes viral production. Among the
inducers of HIV reactivation are T cell receptor (TCR) activation
and inflammatory cytokines such as tumor necrosis factor
(TNF) or interleukin 6 (IL-6) (Chun et al., 1998), whereas the role
of common gamma chain (gc) cytokines such as IL-7 and IL-2
is controversial (Bosque et al., 2011). IL-7 is crucial for T cell
development and homeostasis and participates in survival and
maintenance of memory CD4+ T cells (Kondrack et al., 2003).
During HIV infection, increased levels of IL-7 can be detected,
but they are not sufficient to maintain T cell homeostasis and
CD4+ count progressively declines (Napolitano et al., 2001).
Several clinical trials with IL-7 have been performed in HIV-in-
fected individuals with the goal of increasing the number and
function of lymphocytes, particularly memory cells (Levy et al.,
2009; Le´vy et al., 2012; Sereti et al., 2009; Katlama et al.,
2016). When tested as a potential anti-latency drug, IL-7 pro-
duced T cell proliferation plus low-level viral reactivation (Bosque
et al., 2011), failing to deplete the viral reservoir and even
increasing, at least transiently, the proviral load (Katlama et al.,
2016; Sereti et al., 2009).
HIV-1 infects and replicates in activated CD4+ lymphocytes,
but once the drivers of T cell activation diminish, resting CD4+
lymphocytes are mostly non-permissive for HIV-1 replication.
This is largely due to the absence of essential transcription fac-
tors such as NF-kB and NF-AT (Coiras et al., 2009) and to the
SAMHD1 protein (Descours et al., 2012; Baldauf et al., 2012).
SAMHD1 is a key regulator of cell-cycle progression and a major
viral restriction factor that blocks early reverse transcription of
HIV-1 by depleting the intracellular dinucleotide triphosphate
(dNTP) pool (Lahouassa et al., 2012). It has been proposed
that HIV restriction of SAMHD1 can also be relatedwith degrada-
tion of viral RNA through its RNase activity (Ryoo et al., 2014), but
this concept remains controversial (Seamon et al., 2015). The
function of SAMHD1 is regulated through the phosphorylation
of threonine 592 (T592) by cyclin A2/Cdk1, an event that is
induced by T cell activation and that renders the cells suscepti-
ble to infection by HIV-1 (Cribier et al., 2013). The accessory pro-
tein Vpx of HIV-2 and the simian immunodeficiency virus (SIV)
Figure 1. Kinetics of SAMHD1 Phosphoryla-
tion at T592 in PrimaryCD4+ Lymphocytes in
Response to Different Stimuli
(A) Whole protein extracts from CD4+ T cells
treated with anti-CD3/CD28 for 5 consecutive
days in the presence or not of IL-2 were analyzed
by immunoblotting using a specific antibody
against total and phosphorylated (T592) SAMHD1.
(B) Phosphorylation of SAMHD1 was analyzed by
immunoblotting in whole protein extracts from
CD4+ T cells treated with IL-2 or IL-7 for 5
consecutive days.
(C) Analysis by immunoblotting of the effect on
SAMHD1 phosphorylation of IL-2 or IL-7 depletion
for 48 hr in CD4+ lymphocytes that were previously
treated for 5 days.
(D) Analysis of SAMHD1 phosphorylation by
immunoblotting in CD4+ lymphocytes treated with
chemokines CXCL12 or CXCL9/10 for 5 days, as
well as with IL-2 or IL-7.target SAMHD1 for ubiquitination and proteasomal degradation
(Laguette et al., 2011). As HIV-1 does not encode Vpx, it remains
sensitive to SAMHD1-mediated restriction until T cells receive an
activation signal. We evaluated the effect of gc-cytokines such
as IL-2 and IL-7 and determined that they induced SAMHD1
phosphorylation in CD4+ T cells, promoting susceptibility to
HIV-1 infection. Moreover, as tyrosine kinases are essential dur-
ing T cell activation driven by IL-7 (Johnston et al., 1996), we
observed that the tyrosine kinase inhibitor dasatinib interfered
with SAMHD1 phosphorylation mediated by IL-7, which pre-
serves its antiviral activity and identifies this factor as a potential
therapeutic target.
RESULTS
TCR-Mediated Activation and Homeostatic Stimuli Such
as IL-2 and IL-7 Induced thePhosphorylation of SAMHD1
at T592 in Human CD4+ T Cells
Stimuli such as TCR-mediated activation and gc-cytokines were
analyzed to determine their role in SAMHD1 phosphorylation at
T592 in human primary CD4+ T cells. When CD4+ lymphocytes
were treatedwith anti-CD3/CD28 for 5 days, SAMHD1 phosphor-
ylation initiated after 1 day of TCR-mediated activation (Figure 1A,
left), reaching a peak at day 2 that rapidly decayed. Simultaneous
treatment with IL-2 permitted a sustained SAMHD1 phosphoryla-
tion that remained constant for at least 5 days (Figure 1A, right).
Treatment with IL-2 or IL-7 only induced SAMHD1 phosphoryla-
tion at day 3, which was sustained for at least 5 days (Figure 1B).
A dose-response experiment (Figure 1B, bottom) did not show
significant difference between treatments with low (1 nM) or
high (10 nM) concentrations of IL-7. SAMHD1 phosphorylationCell Reports 14, 2100–210induced by IL-2 or IL-7 was quite stable
as it persisted for at least 48 hr after
removing the cytokines from the culture
medium (Figure 1C, lanes 6 and 7). At the
doses employed, IL-2 and IL-7 caused
T cell proliferation after 10 days of treat-
ment (Figure S1). Treatment of CD4+T cells with chemokines CXCL9, CXCL10, or CXCL12 did not
induce SAMHD1 phosphorylation (Figure 1D, lanes 5 and 6).
The expression of total SAMHD1was notmodified by the addition
of any stimuli to the culture.
IL-2 and IL-7 Induced Reverse Transcription and
Proviral Integration in CD4+ T Cells
To determine the role of IL-2 and IL-7 in HIV-1 reverse transcrip-
tion and proviral integration, primary CD4+ T cells were treated
with IL-2 or IL-7 for 5 days and then infected with X4-tropic
NL4-3_Renilla luciferase strain and cultured for 5 additional
days. Viral reverse transcripts (RTs) were analyzed by qPCR
5 hr post-infection. Low levels of early and late RT were induced
by IL-2 treatment, whereas IL-7 induced an average 13-fold in-
crease in early RT and 43-fold increase in late RT, compared
to IL-2 (p < 0.001; Figure 2A). Both cytokines increased two
long terminal repeat (2-LTR) circles and proviral integration, but
IL-7 was more efficient as it induced an average 2-fold increase
in the number of 2-LTR circles (Figure 2B) and 19-fold increase in
proviral integration as compared to IL-2 (Figure 2C). Similar in-
creases were obtained with R5-tropic strains (data not shown)
and when a wild-type NL4.3 viral clone carrying the nef gene
was used (Figures S2A–S2C). Treatment with CXCL9/CXCL10
chemokines enhanced IL-2-induced viral integration 27-fold
(p < 0.01), whereas simultaneous treatment with CXCL9/
CXCL10 enhanced integration induced by IL-7 only an average
of 2.2-fold (p < 0.05; Figure 2D).
Two lines of evidence suggest that IL-7 function wasmediated
through SAMHD1. First, overexpression of T592A SAMHD1,
a phosphorylation-resistant mutant, decreased IL-2- and IL-7-
mediated infectionwhen transfected in resting CD4 lymphocytes7, March 8, 2016 ª2016 The Authors 2101
Figure 2. Effect of IL-2 and IL-7 on Reverse Transcription and Pro-
viral Integration in HIV-Infected Primary CD4+ Lymphocytes
(A) Analysis by qPCR of the reverse transcription of NL4-3_luciferase strain in
CD4+ lymphocytes treated with IL-2 and IL-7 for 5 days and then infected for
5 hr.
(B and C) The same cells were further cultured for 5 days and then 2-LTRs
circles (B) and proviral integration (C) were quantified by qPCR.
(D) Analysis by qPCR of proviral integration in CD4+ lymphocytes treated with
IL-2 or IL-7 for 5 days and then infected with NL4-3_Renilla luciferase infec-
tious strain and incubated for 5 daysmore in the presence or not of CXCL9 and
CXCL10.
(E) Purified CD4+ T cells were transfected in resting conditions with pOZ-
SAMHD1_WT or pOZ-SAMHD1_T592A and then treated with IL-2 or IL-7 for
4 days. Cells were then infected with NL4-3_Renilla and incubated for 48 hr
before measuring the synthesis of Renilla (RLUs). One representative experi-
ment is shown.
Statistical significance was calculated using two-way ANOVA for (A), one-way
ANOVA for (B) and (C), and Mann-Whitney t test for (D). *p < 0.05; **p < 0.01;
***p < 0.001. All data are represented as mean ± the SEM.
2102 Cell Reports 14, 2100–2107, March 8, 2016 ª2016 The Authorsbefore cytokine activation (Figure 2E). Second, pretreatment
with VLP-Vpx reduced IL7-mediated enhancement of infection
of resting CD4 lymphocytes with HIV-cytomegalovirus (CMV)-
GFP (Figure S2D).
LTR- and NF-kB-Dependent Activation in CD4+ T Cells
Treated with IL-2 or IL-7
The ability of IL-2 and IL-7 to establish latent proviral integration
was determined in primary CD4+ T cells treated with IL-2 or IL-7
for 5 days and infected with NL4-3_Renilla luciferase strain for 5
additional days. Phorbol 12-myristate 13-acetate (PMA) added
18 hr before cell collection produced an average 14-fold and
17-fold increase in viral transcription in cells treated with IL-2
or IL-7 (p < 0.001), respectively (Figure 3A). Treatment with
PMA did not increase proviral integration in CD4+ T cells treated
with IL-7 (Figure S3).
The effect of IL-2 or IL-7 on HIV-1 transcription was also
analyzed in CD4+ T cells treated with IL-2 or IL-7 for 5 days
and then nucleofected with luciferase expression vectors under
the control of the HIV-1-LTR (pLTR-LUC) or three copies of the
NF-kB consensus (p3KB-LUC). Two hours after nucleofection,
cells were incubated with PMA and cultured for 18 hr. Both
IL-2 and IL-7 barely activate LTR- or NF-kB-dependent tran-
scription that was strongly increased by PMA treatment (p <
0.001; Figure 3B).
SAMHD1 Was Preferentially Phosphorylated in Memory
CD4+ T Lymphocytes of HIV-Infected Patients Included
in the ACTG 5214 Study Who Received a Single Dose
of IL-7
To confirm that IL-7 could phosphorylate SAMHD1 in vivo, sub-
populations of CD4+ lymphocytes from nine patients enrolled in
the ACTG 5214 study (Sereti et al., 2009) were analyzed by flow
cytometry. In this study, patients were treated with a single sub-
cutaneous dose of rhIL-7 with doses ranging from 3 to 30 mi-
crog/kg. After selection of living cells (Figure S4), combination
of CCR7 and CD45RAmarkers allowed characterization of naive
(CCR7+CD45RA+), central memory (CCR7+CD45RA), transi-
tional and effector memory (CCR7CD45RA), and terminally
differentiated (CCR7CD45RA+) CD4+ lymphocytes. SAMHD1
phosphorylation significantly increased an average 8.0% in cen-
tral memory cells (p < 0.05) and 7.0% in effector memory cells
(p < 0.05) 4 days after the single injection of rhIL-7 (Figure 4).
Dasatinib Blocked IL-7-Mediated Reverse Transcription
and Proviral Integration
It has been described that gc-cytokines activate pathways
that involve tyrosine kinases (Johnston et al., 1996). Therefore,
primary CD4+ lymphocytes were simultaneously treated for
5 days with IL-7 and dasatinib, an inhibitor of tyrosine ki-
nases—currently used in the treatment of chronic myeloid leuke-
mia (Das et al., 2006). Dasatinib has been described to inhibit
HIV-1 replication at a concentration of 75 nM (Pogliaghi et al.,
2014), and we demonstrated that, at this concentration, it
strongly interfered with SAMHD1 phosphorylation induced by
IL-7 (Figure 5A). As a result, dasatinib interfered with IL-7-medi-
ated viral reverse transcription (Figure 5B) and with proviral inte-
gration (Figure 5C).
Figure 3. IL-7 InducedMostly Latent Proviral
Integration
(A) Measurement of luciferase production (RLUs) in
primary CD4+ T cells treated with IL-2 and IL-7 for
5 days and then infected with NL4-3_Renilla lucif-
erase for 5 days more. PMA was added during the
last 18 hr. SAMHD1 levels were analyzed by
immunoblotting as described in Figure 1.
(B) Analysis of luciferase expression in resting
CD4+ T cells treated with IL-2 or IL-7 for 5 days and
then nucleofected with pLTR-LUC or pkB-LUC
vectors. PMA was added 2 hr post-transfection,
and cells were incubated for subsequent 18 hr.
Statistical significance was calculated using two-
way ANOVA. ***p < 0.001. Data are represented as
mean ± SEM.DISCUSSION
Among the mechanisms for HIV persistence, factors that
extend lifetime and homeostatic proliferation of infected cells
are of paramount importance (Deeks et al., 2012). In this
context, IL-7 is crucial for T cell development and homeostasis
and also participates in the survival and maintenance of mem-
ory CD4+ lymphocytes (Kondrack et al., 2003). IL-7 was first re-
ported to increase HIV replication in peripheral blood mononu-
clear cells (PBMCs) of infected individuals (Smithgall et al.,
1996), in resting CD4+ lymphocytes from patients on ART
(Wang et al., 2005), and in chronically infected human cells
(Scripture-Adams et al., 2002). As a result, IL-7 was originally
proposed as a potential anti-latency agent. Early clinical trials
of IL-7 administration were associated with an increased fre-
quency of ‘‘blips’’ of HIV RNA in plasma among HIV-infected
patients who were receiving suppressive ART (Imamichi
et al., 2011; Le´vy et al., 2012). But although IL-7 can activate
phosphatidylinositol 3-kinase (PI3K) pathways (Venkitaraman
and Cowling, 1994), we and others determined that NF-kB
activity was only slightly increased in CD4+ lymphocytes
treated with IL-7 and is not sufficient to reverse viral latency
(Bosque et al., 2011). Later, it was demonstrated that IL-7
may contribute to the maintenance of HIV reservoirs via ho-
meostatic proliferation (Chomont et al., 2009). In fact, adminis-
tration of IL-7 to HIV-infected patients induced expansion of
CD4+ lymphocytes and increased HIV DNA copy numbers
(Katlama et al., 2016; Sereti et al., 2009).
Because gc-cytokines promote the T lymphocytes cell cycling
and division and because SAMHD1 is regulated by cyclins (Crib-Cell Reports 14, 2100–210ier et al., 2013), we hypothesized that gc-
cytokines might also regulate SAMHD1
activity, leading to an increased suscepti-
bility to HIV-1 infection. We evaluated
the effect of IL-2 and IL-7 on SAMHD1
antiviral activity and determined that
both cytokines induced SAMHD1 phos-
phorylation in primary CD4+ lymphocytes,
thereby eliminating its antiviral activity.
Consequently, IL-7 promoted successful
reverse transcription and subsequent pro-viral integration more efficiently than IL-2. This effect was medi-
ated through SAMHD1 as demonstrated by the use of SAMHD1
T592A mutant and VLP-Vpx, which reduced the IL7-mediated
enhancement of resting CD4 lymphocytes infection. However,
because IL-2 and IL-7 produced a similar pattern of SAMHD1
phosphorylation, an additional mechanism should be contrib-
uting to the higher efficiency of IL-7. It has been described that
actin polymerization dynamics driven by certain chemokines in-
fluence different steps of the pre-integration process (Wu and
Yoder, 2009). Accordingly, as it has been described (Cameron
et al., 2010) that treatment with chemokines CXCL9 and
CXCL10, among others, promote post-integration latency, we
tested their impact in ourmodel.WhenCD4+ T cells were treated
with IL-2 and IL-7 together with CXCL9/CXCL10, stronger inte-
gration in IL-2-cultured lymphocytes was found. However, the
impact of chemokine treatment on IL-7 enhancement of proviral
integration was lower, suggesting that IL-7 could stabilize or
modify actin dynamics as chemokines do. Furthermore, as gc-
cytokines are poor inducers of NF-kB and NFAT, they might be
contributing to the establishment of latent reservoirs. In fact,
HIV-1 expression was incomplete in CD4+ lymphocytes infected
in vitro in the presence of IL-2 or IL-7 as it was further increased
with PMA. Thus, although IL-7 efficiently promoted integration,
latency persisted until a stronger T cell activation signal was
received. TCR-mediated activation induced faster SAMHD1
phosphorylation, which occurs at day 1 after stimulation, but
this phosphorylated form rapidly decayed at day 3. On the other
hand, IL-2 and IL-7 were slower to induce SAMHD1 phosphory-
lation, but they induced a more-stable phosphorylation that was
maintained even after the stimuli were removed. This suggested7, March 8, 2016 ª2016 The Authors 2103
Figure 4. SAMHD1 Phosphorylation in
Different CD4+ T Cell Subsets from HIV-1-
Infected Patients Included in the ACTG
5214 Study Who Received a Single Dose
of IL-7
Surface staining with antibodies against CCR7
and CD45RA allowed distributing cells in the
different CD4+ T cell subsets (depicted in the up-
per drawing). Subsequent intracellular staining
was performed with an antibody against SAMHD1
phosphorylated at T592. Before-after graphs were
depicted for each CD4+ T cell subset. Statistical
significance was calculated using Mann-Whitney
t test. *p < 0.05; ‘‘ns’’ for not significant. Data are
represented as mean ± SEM. The mean percent-
ages and SEM for SAMHD1 phosphorylation at
day 0 and day 4 are shown in the lower table.that SAMHD1 phosphorylation by TCR-mediated activation or
homeostatic cytokines occurred through different mechanisms.
Recent structural work has shown that homotetrameric confor-
mation of SAMHD1 is dependent on diguanosine triphosphate
(dGTP) binding, allowing a more-stable interaction with the sub-
strate. Mutations of dGTP-binding residues in the allosteric site
affect tetramer formation, dNTPase activity, and HIV-1 restriction
(Zhu et al., 2013). It would be important to studywhether SAMHD1
phosphorylation at T592 by IL-2 and IL-7 results in decreased
tetramer formation. Actually, the total amount of SAMHD1 is not
modified by IL-2 or IL-7 treatment, pointing to the generation of
full inactive SAMHD1 in the absence of protein degradation, an
event that could be related with impairment of multimeric com-
plexes formation due to SAMHD1 phosphorylation.
To assess the effect of IL-7 on SAMHD1 phosphorylation
in vivo, we analyzed PBMCs from subjects enrolled in the
ACTG 5214 trial, who received a single injection of rhIL-7 (Sereti
et al., 2009). A significant increase in SAMHD1 phosphorylation
was observed at day 4 in central and effector memory CD4+
lymphocytes from these patients, which was in accordance
with the peak of SAMHD1 phosphorylation observed in vitro after
4 days of IL-7 activation. A sharp increase in cycling—measured
by Ki67 expression—has been described in these patients at
day 4 after IL-7 treatment (Chomont et al., 2009; Sereti et al.,
2009), which strongly correlates with our observed induction
of SAMHD1 phosphorylation. Our own data confirm (Schmidt
et al., 2015) that, in healthy donors, less than 2% of CD4 lympho-
cytes from peripheral blood display phosphorylated SAMHD1.2104 Cell Reports 14, 2100–2107, March 8, 2016 ª2016 The AuthorsBasal levels of phosphorylated SAMHD1
in ACTG 5214 patients were higher and
could be related to the high level of im-
mune activation described in HIV-in-
fected patients even in the presence of
ART. Actually, ACTG 5214 patients dis-
played high levels of lymphocyte activa-
tion as assessed by CD38/HLA-DR
expression (Chomont et al., 2009; Sereti
et al., 2009).
It has been proposed that the persis-
tence of the viral reservoir mostly oc-curs through homeostatic proliferation induced by gc-cyto-
kines such as IL-7 (Chomont et al., 2009). In fact, IL-7
therapy promotes CD4+ expansion in HIV-infected patients
on ART (Le´vy et al., 2012) while concurrently expanding the
pool of provirus-containing CD4+ lymphocytes (Le´vy et al.,
2012; Vandergeeten et al., 2013; Katlama et al., 2016). Our
findings show that IL-7 induced SAMHD1 phosphorylation in
CD4+ lymphocytes, which supported the notion that this cyto-
kine has a role not only in reservoir expansion but also in
increasing the infectivity of memory cells, leading to HIV inte-
gration and reservoir replenishment. Accordingly, impeding
SAMHD1 phosphorylation may represent a valuable target to
increase restriction to HIV-1 infection in CD4+ lymphocytes.
Because gc-cytokines activate JAK/STAT pathways through
tyrosine phosphorylation, we assessed whether the tyrosine
kinase inhibitor dasatinib also prevented SAMHD1 phosphor-
ylation. We demonstrate that inhibition of SAMHD1 phosphor-
ylation by dasatinib strongly decreased HIV reverse transcrip-
tion and integration. Consequently, tyrosine-kinase inhibitors
may represent potential candidates to be used as adjuvants
to ART, in particular in primary infection when viral reservoirs
are established.
In conclusion, we propose a model in which gc-cytokines seed
and replenish the reservoir during suboptimal T cell activation. In
this model, IL-7 and IL-2 would promote SAMHD1 phosphoryla-
tion, making CD4+ lymphocytes more susceptible to HIV-1
infection by facilitating reverse transcription and, subsequently,
proviral integration. However, these gc-cytokines are weak
Figure 5. Cytostatic Drug Dasatinib Inter-
fered with IL-7-Induced SAMHD1 Phos-
phorylation
(A) Analysis by immunoblotting of SAMHD1
phosphorylation in CD4+ T cells isolated from
healthy donors that were treated with IL-7 for
5 days in the presence of dasatinib.
(B and C) Viral reverse transcription (B) and pro-
viral integration (C) were analyzed by qPCR in
CD4+ T cells treated with IL-7 for 5 days in the
presence or not of dasatinib and infected with
NL4-3_Renilla luciferase strain for subsequent
5 days.
(D) Luciferase activity was measured in cell ex-
tracts 48 hr after infection.
Statistical significance was calculated using two-
way ANOVA for (B) and Mann-Whitney t test
for (C). *p < 0.05. Data are represented as
mean ± SEM.inducers of viral transcription (Bosque et al., 2011), and therefore,
IL-7 and IL-2 would maintain preferentially the provirus in latency.
It cannot be discarded that IL-2 and IL-7 contribute to blips or
low persistent viremia that can be detected in patients on ART
(Coiras et al., 2009; Imamichi et al., 2011). Consequently, IL-7
would fulfill three essential roles in HIV-1 persistence: reservoir
seeding through SAMHD1 phosphorylation, low ongoing expres-
sion via NF-kB activity, and reservoir maintenance through ho-
meostatic proliferation. In this model, full activation of proviral
transcription through TCR-mediated activation or inflammatory
cytokine exposure would drive robust viral replication and CD4
depletion.
EXPERIMENTAL PROCEDURES
Cells
PBMCs were isolated from healthy donors by Ficoll-Hypaque gradient (GE
Healthcare). Primary CD4+ T cells were isolated using CD4+ T Cell Isolation
Kit (Miltenyi Biotec).
Patients
Blood samples of patients treated with IL-7 belong to ACTG5214 study. This
studywas approved by the institutional review boards (IRBs) of all participating
sites, and written informed consent was obtained from all participants in
accordance with the Declaration of Helsinki (NCT 00099671; as stated in Sereti
et al., 2009).Cell Reports 14, 2100–210Blood from nine patients enrolled in ACTG 5214
study were collected before rhIL-7 administration
(day 0) and 4 days after injection. All participants
received a single dose of subcutaneous human
recombinant IL-7 on day 0 at doses ranging
3–30 mg/kg. Details of the clinical trial
(NTC00099671) have been previously published
(Sereti et al., 2009).
Reagents and Antibodies
IL-2 (Chiron) was used at 300 U/ml. IL-7 (R&D Sys-
tems) was used at 1 nM across most experiments.
Purified anti-human CD3 (clone OKT3) and CD28
(clone CD28.2) were used for T cell activation
(eBiosciences). CXCL9 and CXCL10 (R&D Sys-
tems) were used at 0.1 mM. CXCL12 was used at50 nM and was kindly provided by Dr. Franc¸oise Baleux (Institut Pasteur).
PMA (Sigma-Aldrich) was used at 25 ng/ml. A polyclonal antibody against
SAMHD1 phosphorylated at T592 was used for immunoblotting, and a mono-
clonal antibody conjugated with Alexa Fluor 647 (Life Technologies) was used
for flow cytometry. Both antibodies were generated at Institute of Human Ge-
netics. Validation of the murine monoclonal antibody against SAMHD1 phos-
phorylated at T592 was performed in TH1 cells. Titration of the epitope speci-
ficity was performed by preincubation of the antibody with immunizing peptide
before incubation on cells (Figure S5A). Phosphorylated SAMHD1 showed a
predominant nuclear localization (Figure S5B). Antibody against total SAMHD1
was purchased from Bethyl Laboratories. Dasatinib (Sprycel; Bristol-Meyers
Squibb) was kindly provided by Dr. Stephen Mason and Dr. Carey Hwang.
Vectors
pLTR-LUC, p3kB-LUC (Arenzana-Seisdedos et al., 1993), the pNL4.3-Renilla
luciferase replication competent viral clone (Garcia-Perez et al., 2007), pOZ-
SAMHD1-WT, and T592 mutant expression vectors (Cribier et al., 2013)
have been previously described.
HIV-1 Infection
Primary CD4+ T cells were infected by spinoculation, as previously described
(Lo´pez-Huertas et al., 2011). Luciferase was measured using Renilla Lucif-
erase Assay System (Promega) with a Sirius luminometer (Berthold).
Transfection Assays
CD4+ T cells were transiently transfected in resting conditions by electropora-
tion at 300 V, 1,500 mF,NU at a concentration of 20 million per cuvette, 1 mg
DNA plasmid per million of cells.7, March 8, 2016 ª2016 The Authors 2105
Immunoblotting
Whole protein extracts were fractionated by SDS-PAGE and transferred onto
Hybond-ECL nitrocellulose paper (GE Healthcare). Proteins were detected
with SuperSignal West Pico Chemiluminescent Substrate (Pierce).
Flow Cytometry Multicolor Assay
Analysis of different CD4+ T cells subsets was performed after staining
with anti-CD4-PeCy7 (OKT4; BioLegend), anti-CCR7-FITC (3D12), and anti-
CD45RA-PE (HI100; BD Biosciences). Cells were fixed with paraformaldehyde
1%, permeabilized with methanol, and probed with anti-SAMHD1 phosphory-
lated at T592 conjugatedwith Alexa Fluor 647. Data acquisitionwas performed
in a fluorescence-activated cell sorting (FACS) Canto flow cytometer (BD Bio-
sciences). Data processing and analysis were done using FACS Diva software
and Flowing software v2.5.1.
qPCR
Strong stop DNA was quantified using primer pairs specific for R and U5 re-
gions of the HIV LTR as described (Mohammadi et al., 2013). Episomal forms
of 2-LTR and integrated HIV-1 proviral DNA were quantified by conventional
and qPCR, respectively, as described (Buzo´n et al., 2010). A standard curve
of integrated DNA from 8E5 cell line was prepared, and ccr5 gene was used
as housekeeping. Conventional PCRwas performed in a C1000 thermal cycler
(Bio-Rad), and qPCR was performed in a StepOnePlus Real-Time PCR Sys-
tem, using StepOne v3.2 software (Life Technologies).
Statistical Analysis
Statistical analysis was performed using Graph Pad Prism 5.0 (Graph Pad
Software). Comparisons between two groups were made using two-tailed
Mann-Whitney test. Comparisons between more than two groups were
made using two-way ANOVA with Bonferroni post test analysis.
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